SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

USO is trending due to escalating geopolitical tensions in the Middle East, specifically following reports of US-Israeli strikes on Iran, which is fueling intense community debate about potential oil supply disruptions, particularly through the Strait of Hormuz. Investors are sharply divided between anticipating a significant oil price spike and expecting a 'sell the news' reversal.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is trending amidst escalating US-Iran conflict, with strikes on Gulf infrastructure and threats to the Strait of Hormuz fueling widespread fears of global oil supply disruptions and significant crude price surges. The community is actively discussing a flight to energy assets, positioning the sector for strong momentum even as broader markets anticipate risk-off sentiment.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

The defense community is buzzing about Kratos Defense & Security Solutions, navigating a recent substantial stock offering against a wave of new contracts for its leading drone and hypersonic systems. Investors are keenly focused on the company's pivotal role in evolving global defense priorities and the anticipated surge in military spending.

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Aardvark Therapeutics Inc.

Aardvark Therapeutics Inc

Aardvark Therapeutics is facing intense scrutiny and negative sentiment after voluntarily pausing its Phase 3 HERO trial for ARD-101 due to reversible cardiac safety signals observed in high-dose studies. The community is expressing significant concern about the drug's future and the company's prospects in the competitive Prader-Willi Syndrome treatment landscape.

Vanguard Group, Inc. - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is trending amidst heightened market uncertainty driven by Federal Reserve policy, geopolitical developments, and ongoing debates about the sustainability of valuations in the tech sector. Despite some community calls for a significant correction, many investors continue to favor VOO for its broad market exposure and long-term stability.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devon Energy is trending after solidifying its merger with Coterra Energy, a deal poised to create a new U.S. oil and gas giant with expanded production and a focus on significant shareholder returns through increased dividends and buybacks. Investors are also monitoring ongoing geopolitical tensions, which are sparking broader interest in the energy sector.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is a focal point of intense market and social media discussion following significant military action against Iran, including the reported death of its Supreme Leader, as investors and community members weigh the geopolitical implications and ongoing controversies.

Canton Coin (CC), the network’s native utility token, was designed to reward real network usage over speculation. It aligns the success of the network with the participants who make it work, fairly rewarding app builders and app users, as well as those operating decentralized infrastructure. The result is a fundamentally different model where rewards flow to those creating value through real activity, not only miners or early investors.

Canton

The $CC symbol is trending amid excitement for Canton's recent exchange listings and its Real World Asset (RWA) potential, although a significant portion of the community discussion is currently driven by "Community Coin," a charity project gaining attention for its recent donations and philanthropic model.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad (MON) is trending due to recent ecosystem integrations, including Kalshi deposits and Orbs perpetuals, coupled with a notable CNBC mention and significant institutional backing. The community is actively discussing its high-performance Layer-1 technology, attractive 12% staking yield, and perceived long-term potential as it shows resilience in a volatile crypto market.

BlackRock Institutional Trust Company N.A. - iShares U.S. Aerospace & Defense ETF

iShares Dow Jones US Aerospace & Defense

ITA is trending as intensified global conflicts, especially in the Middle East and Eastern Europe, drive community discussion around a new era of increased defense spending and military modernization. Investors are closely monitoring the sector's potential for growth, despite some mixed sentiment regarding market-specific factors and broader geopolitical implications.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What is Lifesci Capital's Estimate for LRMR FY2025 Earnings?

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities researchers at Lifesci Capital issued their FY2025 EPS estimates for Larimar Therapeutics in a note issued to investors on Tuesday...

<ul class="summary-bullets"><li>Wall Street looks set for a cautious open despite Nvidia’s strong quarter, with traders focused on China exposure.</li><li>Warner Bros. Discovery is set to report earnings before the bell.&nbsp;</li><li>On the macro front, investors will parse weekly jobless claims at 8:30 a.m. ET.&nbsp;</li></ul>U.S. stock futures were mixed early Thursday, with traders bracing for a choppy session. While AI bellwether Nvidia delivered a blowout earnings report, concerns over its access to the Chinese market, along with disappointing guidance from software giants like Salesforce and C3.ai, are weighing on investor sentiment.Investors will also be watching for developments as the U.S. and Iran hold their latest round of talks in Geneva today amid military threats.&nbsp;As of 3:00 a.m. ET on Thursday, Nasdaq futures were down 0.1%, Dow futures were down 0.2%, and S&amp;P 500 and Russell 2000 futures were flat, with a positive bias.Meanwhile, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, has flipped to ‘bullish’ from ‘neutral’ a day ago, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bearish’ amid high message volumes.&nbsp;Trending Stocks To WatchNvidia (NVDA):&nbsp;It was the top trending ticker on Stocktwits at the time of writing. The stock pared its gains in after-hours trading as concerns over China's revenue outlook lingered. CFO Colette Kress confirmed that the current forecasts exclude China revenue. This comes even as the chipmaker has secured a license to ship a small number of its less advanced H200 chips to Beijing, subject to inspection and a 25% duty.&nbsp; Netflix (NFLX), Warner Bros Discovery (WBD) &amp; Paramount (PSKY):&nbsp;Investors are closely tracking the developments in the merger drama, with traders speculating that the streamer may walk away from its bid for Warner Bros. Discovery. Paramount has now upped its stakes with a $31/share offer, while Netflix's co-CEO is reportedly heading to White House to discuss the merger’s regulatory issues. Also, keep an eye on WBD, which reports earnings today.&nbsp;Salesforce (CRW):&nbsp;The software giant’s fiscal 2027 revenue guidance missed Wall Street’s expectations, overshadowing its strong Q4 earnings report.&nbsp;C3.ai (AI):&nbsp;A wider-than-expected loss and announcement of workforce cuts is weighing on trader sentiment.&nbsp;Apple (AAPL):&nbsp;Report suggest that the iPhone maker is in talks with major Indian banks to launch its payments service in India by mid-2026.&nbsp;Larimar Therapeutics Inc. (LRMR):&nbsp;The pharma company has priced an upsized $100 million stock offering. The deal was upsized from the earlier-announced $75 million offering and comes after the FDA’s Breakthrough Therapy designation for Nomlabofusp, earlier this week. It was among the top trending tickers on Stocktwits at the time of writing.&nbsp;ImmunityBio Inc. (IBRX):&nbsp;The retail favourite pharma stock remains in focus ahead of the ASCO Genitourinary Cancers Symposium (Feb. 26–28).&nbsp;Watch out for rare-earth stocks in trade today (CRML, MP, UUUU), following a report that suppliers to U.S. aerospace and semiconductor firms are reporting worsening shortages in the market.&nbsp;And copper stocks (FCX, RIO, SCCO, HBM) could see some actiontoday, with copper futures on track for their seventh straight monthly advance.&nbsp; Other tickers trending on Stocktwits at the time of writing included Snap Inc (SNAP), Trade Desk Inc (TTD), Joby Aviation (JOBY), and Sarepta Therapeutics (SRPT), among others.&nbsp;Other Catalysts To WatchOn the economic front, investors will monitor the weekly jobless claims release at 8:30 am. Also, Federal Reserve Vice Chair for Supervision Michelle Bowman is scheduled to testify before Congress later today.&nbsp; On the earnings radar, investors will be watching for the quarterly reports from Warner Bros. Discovery (WBD), Baidu (BIDU), Celsius (CELH), Shake Shack (SHAK), and J.M. Smucker (SJM), among others, before the bell today. Notable companies reporting earnings after market close include Intuit (INTU), Dell Technologies (DELL), TeraWulf (WULF), Rocket Lab (RKLB), and SoundHound AI (SOUN), among others.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today

Data from Stocktwits showed that retail sentiment on SPY and QQQ diverged. 

Equity

<ul class="summary-bullets"><li>The company priced an upsized $100 million stock offering, following a record 61% surge in Wednesday’s regular session.</li><li>On Tuesday, the FDA granted Breakthrough Therapy Designation to Nomlabofusp, Larimar’s frataxin protein replacement therapy for Friedreich’s ataxia.</li><li>The company remains on track to submit a BLA in June and expects topline data in Q2.</li></ul>Shares of Larimar Therapeutics Inc. (LRMR) surged over 60% on Wednesday to their strongest session on record before pricing an upsized $100 million stock offering, extending gains following the FDA’s Breakthrough Therapy designation for Nomlabofusp.<h2 class="st-heading-2">Larimar Prices Upsized $100M Stock Offering</h2>Late Wednesday, the biotech firm said it priced 20 million shares of common stock at $5 per share, raising gross proceeds of nearly $100 million before underwriting discounts and expenses.The deal was upsized from the earlier-announced $75 million offering. Larimar also granted underwriters a 30-day option to purchase up to an additional 3 million shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on Thursday.Larimar intends to use the net proceeds to support the development of Nomlabofusp, its Breakthrough Therapy-designated frataxin protein replacement treatment for a neurodegenerative disorder, as well as working capital and general corporate purposes, including research and development and commercialization expenses.<h2 class="st-heading-2">FDA Grants Breakthrough Status To Nomlabofusp</h2>The equity raise comes just one day after Larimar said that the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-larimar-therapeutics-stock-surge-pre-market-today/cZRvC02R4CO">FDA granted</a> Breakthrough Therapy Designation to Nomlabofusp, its frataxin protein replacement therapy for adults and children with Friedreich’s ataxia, a rare inherited neurodegenerative disorder.The designation is intended to expedite development and regulatory review for therapies that may offer substantial improvement over available treatments.The FDA’s decision was based on preliminary data from Larimar’s ongoing open-label study. The company said treatment raised frataxin levels in patients’ skin to amounts typically seen in people who carry the gene mutation but do not develop symptoms. After one year, patients also showed consistent improvement across four key measures of the disease, including overall neurological function, daily living activities, hand coordination and fatigue.The agency also reaffirmed its willingness to consider skin frataxin levels as a novel surrogate endpoint reasonably likely to predict clinical benefit, supporting Larimar’s planned Biologics License Application (BLA) seeking accelerated approval.<h2 class="st-heading-2">BLA Timeline And Phase 3 Plans Remain On Track</h2>Larimar said it remains on track to submit a BLA in June. Topline data from the open-label study to support the filing are expected in the second quarter of this year.The company also plans to initiate screening in a global confirmatory Phase 3 study in the second quarter of 2026, with first patient dosing expected by mid-2026. If approved, a U.S. launch is targeted for the first half of 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for LRMR was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/lrmr_ss_png_14eb5c6335.webp" alt="lrmr ss.png" width="968" height="143"><figcaption>LRMR sentiment and message volume as of February 25 | Source: Stocktwits</figcaption></figure>One user said, “back at $6 hope to open at $7-$8 tomorrow.”<stembedurl>https://stocktwits.com/Fa07/message/645927469</stembedurl>Another user said, “They’ll get this drug pushed through and the share price will be 15-20 very soon.”<stembedurl>https://stocktwits.com/mrtallman/message/645936108</stembedurl><a href="https://stocktwits.com/symbol/LRMR">LRMR stock</a> has jumped 56% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

LRMR stock has jumped 56% year to date. (Photo credit: Getty Images)

Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy

Larimar (LRMR) company priced 20 million shares at $5 each, upsized from a previously announced $75 million raise.

The company priced 20 million shares at $5 each, upsized from a previously announced $75 million raise.

Best Small Cap Stocks To Follow Today - February 25th

Larimar Therapeutics, AltC Acquisition, XWELL, Direxion Daily PLTR Bear 1X Shares, and Vale are the five Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap...

Citigroup Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $14.00

Citigroup upped their target price on Larimar Therapeutics from $12.00 to $14.00 and gave the stock a "buy" rating in a report on Wednesday...

Larimar Therapeutics (NASDAQ:LRMR) Hits New 1-Year High After Analyst Upgrade

Larimar Therapeutics (NASDAQ:LRMR) Sets New 12-Month High on Analyst Upgrade...

Biotech Stocks To Follow Today - February 25th

ImmunityBio, Larimar Therapeutics, and United Therapeutics are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded...

Larimar Therapeutics Sees Unusually High Options Volume (NASDAQ:LRMR)

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) was the target of some unusual options trading on Wednesday. Traders acquired 3,744 call options on the company. This represents an increase...

Larimar Therapeutics' (LRMR) Outperform Rating Reaffirmed at Wedbush

Wedbush reaffirmed an "outperform" rating and issued a $11.00 price objective on shares of Larimar Therapeutics in a research note on Wednesday...

Lifesci Capital Upgrades Larimar Therapeutics (NASDAQ:LRMR) to "Strong-Buy"

Lifesci Capital upgraded Larimar Therapeutics to a "strong-buy" rating in a research note on Tuesday...

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

LRMR
Larimar Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LRMR News

LRMRLarimar Therapeutics Inc